Evidence map›Paper›PMID 35834026›Full record

ReviewMedical oncology (Northwood, London, England)2022

Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice.

Giandomenico Roviello, Martina Catalano, Carlotta Ottanelli, Roberta Giorgione, Virginia Rossi, Elisabetta Gambale, Chiara Casadei, Ugo De Giorgi, Lorenzo Antonuzzo

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Advances inPharmaceutics · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Giandomenico RovielloDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini, 6, 50139, Florence, Italy. giandomenicoroviello@hotmail.it.ORCID http://orcid.org/0000-0001-5504-8237
Martina CatalanoSchool of Human Health Sciences, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
Carlotta OttanelliSchool of Human Health Sciences, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
Roberta GiorgioneSchool of Human Health Sciences, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
Virginia RossiMedical Oncology Unit, Careggi University Hospital, 50134, Florence, Italy.
Elisabetta GambaleMedical Oncology Unit, Careggi University Hospital, 50134, Florence, Italy.
Chiara CasadeiIRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy.
Ugo De GiorgiIRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy.
Lorenzo AntonuzzoMedical Oncology Unit, Careggi University Hospital, 50134, Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment landscape for metastatic castration-resistant prostate cancer has evolved extremely in recent years and several drug classes are now available. Nonetheless, the lack of validated predictive biomarkers makes therapeutic choice and the best sequential approach difficult. The location of the metastatic site could be a valid criterion for choosing among the treatment options available. Although bone remains the most frequent metastatic site and a possible target for many drugs, recent data suggest a profound shift in the disease spectrum with visceral metastases increasing incidence. This review describes the presently available and ongoing therapies for patients with CRPC and bone metastases, focusing on the role of bone metastases as a possible driver for selecting therapies in these patients.

Indexed as

Bone NeoplasmsProstatic Neoplasms, Castration-ResistantHumansMaleNitrilesNitriles177Lu-PSMA-617Androgen receptor signaling inhibitorsBone metastasesChemotherapyMetastatic castration-resistant prostate cancerPARP inhibitorsradium223Sipuleucel-T

Identifiers

PMID35834026

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.